Meds & Supplements, News & Research, Treatment

FDA to Review “New” Migraine Drug

The FDA has accepted for review a “new” migraine drug, Trexima, that was developed by Pozen for sale by GlaxoSmithKline. Trexima is a combination of sumitriptan (Imitrex) and naproxen sodium (the ingredient in Aleve).

Hmm, could this be GSK’s desperate attempt to hold the patent (set to expire in 2009) on a drug that brings in loads of money? Patients who spend small fortunes on triptans each year would probably be willing to forego the convenience of taking one pill instead of two.

You gotta love CNN’s headline: Glaxo’s New Drug May Save Migraine Sales. Who knew that you could buy and sell migraine. I’d be happy to put mine up for sale. Think anyone would buy it on eBay?

4 thoughts on “FDA to Review “New” Migraine Drug”

  1. Now you’ve got me going on how to list my headache.

    One long term chronic daily headache. Minimum one year old, shifts between pain levels 2 – 5 with occasional spikes up to 8 if you’ve been very very bad. If you have the high bid for this headache you will have to give up beer, wine, and loud events. You will get to try a random assortment of drugs meant for other ailments. No shipping fee, supply of beta-blockers included.

Leave a Reply

Your email address will not be published. Required fields are marked *